Keeping you up to date on recent developments in neurology, including: Understanding ‘brain fog’ in people with COVID-19; AD diagnostics could become more accessible; Careful with that BBB.
A study led by scientists at the Korean Research Institute of BioScience and Biotechnology in Daejeon is the first to demonstrate that Dilp8/INSL3-Lgr3/8-NUCB, neuropeptide y signaling may be a potential therapeutic target in cancer anorexia and cachexia, which is associated with increased cancer mortality.
As of the end of January, SARS-CoV-2 has demonstrably infected more than 100 million individuals globally. It has killed more than 2 million. And the long-term sequelae of COVID infections – to say nothing of the health consequences of grief, social isolation and widespread economic distress – are still unfolding and will be for years to come.
Keeping you up to date on recent developments in diagnostics, including: Prostate cancer risk scores; Predicting phase separation; iPSCs give sneak preview of AML.
Twenty years to the month after the completion of the draft sequence of the human genome, the Human Genome Project and follow-on projects like The Cancer Genome Atlas are underpinning advances in precision medicine.
Keeping you up to date on recent developments in orthopedics, including: Hot nano-chisel used to create artificial bones in a Petri dish; A 'skeletal age' calculator to predict bone fracture risk; Fetal surgery for spina bifida leads to better mobility in school-age children.
Australian researchers at the Walter and Eliza Hall Institute of Medical Research in Melbourne have developed new yeast- and antibody-based methods to determine how tryptophan C-mannosylation, an unusual protein glycosylation modification, impacts the stability and function of disease-relevant proteins.
KRAS is the most frequently mutated oncogene in solid tumors in general, and in lung tumors in particular. There are more patients whose lung tumors are driven by KRAS mutations than by ALK, Ros, Ret and TRK alterations. Combined. And after 40 years, they look to be getting a targeted therapy, or even two.
KRAS is the most frequently mutated oncogene in solid tumors in general, and in lung tumors in particular. There are more patients whose lung tumors are driven by KRAS mutations than by ALK, Ros, Ret and TRK alterations. Combined. And after 40 years, they look to be getting a targeted therapy, or even two.
RSS
